U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE.
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10784397
Filing Date		2004-02-23
First Named Inventor	Jodie	Lynn Reynolds
Art Unit		2621
Examiner Name		
Attorney Docket Numb	or	60316/4

Initial*	Cite No	Patent Number	Kind Code ¹	Issue D)ate	Name of Patentee or Applicant of cited Document		Releva	,Columns,Li ant Passage s Appear		ent
	1	6356545	B1	2002-03	I-12	Vargo et al.					
	2	5517246		1996-05	i-14	Suzuki					
	3	6968006	B1	2005-11	I-22	Pun et al.					
If you wis	h to a	dd additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner	Cite		ber Kind Publication Name of Patentee or Application of cited Document			Pages	,Columns,Li	ines where			
Initial*	No	Publication Number			tion				ant Passage s Appear	s or Releva	int
		Publication Number								s or Releva	int
Initial*	No 1		Code ¹	Date 2002-05	i-23	of cited Docu	iment	Figure	s Appear	s or Releva	int
Initial*	No 1	20020062482	A1	Date 2002-05 plication	i-23 n citatio	of cited Docu	please click the Ad	Figure	s Appear	s or Releva	int
Initial*	No 1	20020062482	A1	2002-05 plication	i-23 n citatio	of cited Docu Bolle et al. information p ENT DOCUM Publication	please click the Ad	Figure d button	s Appear	mns,Lines vant r Relevant	Int Ts

U.S.PATENTS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10784397
iling Date		2004-02-23
irst Named Inventor	Jodie	Lynn Reynolds
Art Unit		2621
xaminer Name		
Attorney Docket Numb	er	60316/4

	2	088947	71	EP	B1	2004-06-05	AT&T Corp.		
If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
NON-PATENT LITERATURE DOCUMENTS Remove									
Examiner Cite Initials* Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposisum, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							Тб		
	1 Office Action mailed March 26, 2007, for Application No. 10/256,266, filed September 26, 2002								
If you wish to add additional non-patent literature document citation information please click the Add button Add									
EXAMINER SIGNATURE									
Examiner Signature Date Considered									
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a									

See Kind Codes of USPTO Petent Documents at invest, ISPTO, DDL/or KMPEP 601.04. 2 Enter office that issued the document, by the involved code (WIPO) Standard S13.3 - For Lapraence parter fourments, the articulation of the parent of the register or the present or the serial review of the patient document. A found of coursent by the spropriate symbols as indicated on the document under WIPO Standard S11.6 if possible, "Applicant is to place a check mark here if English tarquages transitions in statistics."

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10784397			
Filing Date		2004-02-23			
First Named Inventor	Jodie	Lynn Reynolds			
Art Unit		2621			
Examiner Name					
Attorney Docket Numb	or	60316/4			

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 1.97(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 177(40).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

_ ...

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Kory D. Christensen/	Date (YYYY-MM-DD)	2007-04-16
Name/Print	Knry D. Christensen	Registration Number	43 548

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandriva, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.